Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

63.32 +0.01 (+0.02%)
Streaming Delayed Price Updated: 1:38 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
Twitter And 3 Other Stocks Insiders Are Selling
US crude oil futures traded sharply lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
Four pharmaceutical stocks, including three biotech movers, are making big moves. 
Via Investor's Business Daily
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss
Via Benzinga
4 Analysts Have This to Say About Incyte
Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter: 
Via Benzinga
Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance
Via Benzinga
7 Defensive Stocks to Buy for a Bear Market
As Wall Street gets ready for another earnings season, investors are increasingly chasing after defensive stocks to buy for a bear market. 
Via InvestorPlace
Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Tuesday, June 14
CNBC 
Via Benzinga
Incyte: Q1 Earnings Insights
Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy
Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration. 
Via Benzinga
Insights On Incyte Corporation
In the first quarter of 2022, Incyte Pharmaeuticals reported very strong quarterly results, highlighted by the launch of Opzelura. The launch continues to perform well, with Q1'22 sales of $13 million... 
Via Talk Markets
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review
A confirmed market uptrend is reeling as inflation's pain bites. 
Via Investor's Business Daily
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted
Via Benzinga
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
Via Benzinga
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
The race is on in eczema treatment as the biggest name faces new rivals. 
Via Investor's Business Daily
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19
The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M
Global Cord Blood Corporation (NYSE: CO) will acquire Cellenkos Inc and the rights to develop and commercialize all of its existing and future products worldwide. 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
3 Nasdaq Stocks to Buy Now for Growth
These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year. 
Via InvestorPlace
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
From Incyte
Via Business Wire
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.